• Karyopharm will present Phase 3 SENTRY data at ASCO 2026; results were published simultaneously in the Journal of Clinical Oncology.
• Selinexor with ruxolitinib improved spleen response versus ruxolitinib alone, supporting a stronger efficacy profile for first-line myelofibrosis.
• Symptom improvement was broadly similar between arms, reducing the likelihood of a differentiated patient-reported benefit.
• Overall survival trended in favor of the combination, an outcome that could strengthen the regimen’s commercial positioning if confirmed.
• Safety was described as manageable with no new signals, though severe side effects were more frequent with the combination.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606020859PR_NEWS_USPR_____NE73005) on June 02, 2026, and is solely responsible for the information contained therein.